NCT05621252View on ClinicalTrials.gov

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

December 27, 2023

Study Completion Date

January 8, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

PLN-74809

160 mg PLN-74809

DRUG

Placebo

Matching placebo

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Pliant Therapeutics, Inc.

INDUSTRY

NCT05621252 - Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | Biotech Hunter | Biotech Hunter